Loss of Heterozygosity (LOH) Affecting HLA Genes in Breast Cancer: Clinical Relevance and Therapeutic Opportunities
Genes · 2024
DOI: 10.3390/genes15121542 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes, 2024. Verfasst von María Antonia Garrido und 4 weiteren Autor:innen. Beteiligte Einrichtung: Radiology Service, Virgen de la Nieves University Hospital, 18014 Granada, Spain. Hauptthemen laut MEDLINE: Loss of Heterozygosity, Breast Neoplasms, HLA Antigens. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Innovation Spain, Andalusian Government and confounding by FEDER funds (, the Ministry of Science and Innovation.
Abstract (Originalsprache)
Major histocompatibility complex (MHC) class-I molecules (or Human Leucocyte Antigen class-I) play a key role in adaptive immunity against cancer. They present specific tumor neoantigens to cytotoxic T cells and provoke an antitumor cytotoxic response. The total or partial loss of HLA molecules can inhibit the immune system’s ability to detect and destroy cancer cells. Loss of heterozygosity (LOH) is a common irreversible genetic alteration that occurs in the great majority of human tumors, including breast cancer. LOH at chromosome 6, which involves HLA genes (LOH-HLA), leads to the loss of an HLA haplotype and is linked to cancer progression and a weak response to cancer immunotherapy. Therefore, the loss of genes or an entire chromosomal region which are critical for antigen presentation is of particular importance in the search for novel prognostic and clinical biomarkers in breast cancer. Here, we review the role of LOH-HLA in breast cancer, its contribution to an understanding of cancer immune escape and tumor progression, and discuss how it can be targeted in cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Radiology Service, Virgen de la Nieves University Hospital, 18014 Granada, Spain.
- Department of Biochemistry, Molecular Biology III and Immunology, School of Medicine, University of Granada, 18016 Granada, Spain.
- Biosanitary Research Institute of Granada (ibs.GRANADA), 18012 Granada, Spain.
- Department of Genomic Medicine, Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO), 18016 Granada, Spain.
- Department of Radiology and Physical Medicine, School of Medicine, University of Granada, 18016 Granada, Spain.
- CIBER of Epidemiology and Public Health (CIBERSP), 28034 Madrid, Spain.
ORCID-Profile: Natalia Aptsiauri
Förderung
- Ministry of Science and Innovation Spain
- Andalusian Government and confounding by FEDER funds (
- the Ministry of Science and Innovation
- Andalusian Government
Zitieren
APA
Garrido, M. A., Navarro-Ocón, A., Ronco-Díaz, V., Olea, N., & Aptsiauri, N. (2024). Loss of Heterozygosity (LOH) Affecting HLA Genes in Breast Cancer: Clinical Relevance and Therapeutic Opportunities. Genes. https://doi.org/10.3390/genes15121542
Vancouver
Garrido MA, Navarro-Ocón A, Ronco-Díaz V, Olea N, Aptsiauri N. Loss of Heterozygosity (LOH) Affecting HLA Genes in Breast Cancer: Clinical Relevance and Therapeutic Opportunities. Genes. 2024. doi:10.3390/genes15121542
BibTeX
@article{Garrido2024,
author = {Garrido, María Antonia and Navarro-Ocón, Alba and Ronco-Díaz, Víctor and Olea, Nicolás and Aptsiauri, Natalia},
title = {Loss of Heterozygosity (LOH) Affecting HLA Genes in Breast Cancer: Clinical Relevance and Therapeutic Opportunities},
journal = {Genes},
year = {2024},
doi = {10.3390/genes15121542}
}
EUVIMED